Copyright Clearance Center

NOVEMBER 7, 2023

CCC , a pioneer in voluntary collective licensing, advancing copyright, accelerating knowledge, and powering innovation, announces Clinical Trial Registries, a new data connector for customers of the cloud-based software solution RightFind Navigate. November 7, 2023 – Danvers, Mass. –

Management 115

Management 115

Copyright Clearance Center

SEPTEMBER 28, 2023

RightFind Navigate unifies searching across multiple licensed content sources, publicly available data, and internal proprietary content, empowering researchers to reveal connections and drive innovation.

Management 111

Management Pharmaceutical 111

Pharmaceutical Technology

NOVEMBER 9, 2022

CSL Behring has a commercialisation and license agreement to develop EtranaDez. million price tag. The post Can gene therapies for haemophilia defend their high price tags? A fair price for CSL Behring’s haemophilia B treatment etranacogene dezaparvovec would be between $2.93–2.96 million ($1.8 million at the time).

Safety 111

Safety Pharmaceutical Patients Medicine 111

Pharmaceutical Technology

APRIL 13, 2023

Although the findings in the report are only preliminary, they shed light at the considerations behind the high price tags of gene therapies. While Vertex and CRISPR submitted the Biologics License Application (BLA) for exa-cel earlier this April, bluebird has yet to do so for lovo-cel.

Healthcare 59

Healthcare Healthcare Pharmaceutical FDA 59

Spotio

JUNE 17, 2022

Factiva’s global database of nearly 33,000 premium sources — including licensed publications, influential websites, blogs, images, and video — gives users powerful insights. NerdyData is a search engine designed to find the code, tools, and licenses your competitors or your prospects’ competitors are using. 26: NerdyData. Performance.

Sales Management 52

Sales Management Management Sales Prospecting 52

Pharmaceutical Technology

JUNE 21, 2023

The high price tag may be hard to defend , but with lifetime treatment costs for haemophilia B reaching as high as $23m for some, the single-dose treatment could prove far more cost-effective. Already a big player in haemophilia treatments, CSL licensed exclusive global rights to Hemgenix from gene therapy developers uniQure back in 2021.

Patients 98

Patients Food and Drug Administration Engineering Sales 98